Jaguar Health (JAGX) Registration filing summary

Company overview and business model

• Develops proprietary prescription drugs from plant sources for complex gastrointestinal diseases in humans and animals, with a focus on orphan and rare conditions through subsidiaries and joint ventures.

• Key products include FDA-approved Mytesi for HIV/AIDS-related diarrhea and Canalevia-CA1 for chemotherapy-induced diarrhea in dogs; both are crofelemer-based.

• Expanding crofelemer indications to cancer therapy-related diarrhea, microvillus inclusion disease (MVID), and short bowel syndrome with intestinal failure (SBS-IF).

• Holds global unencumbered rights for crofelemer and is pursuing regulatory approvals and orphan drug designations in the US and EU.

Financial performance and metrics

• Received $16 million non-dilutive capital in January 2026 from a licensing agreement, with an additional $2 million pending and up to $20 million in future milestone payments.

• May receive up to $40 million in gross proceeds from the equity line of credit, depending on share sales and market price.

Use of proceeds and capital allocation

• Proceeds from the equity line will be used for working capital, general corporate purposes, and redemption of Series P Preferred Stock.

• Management retains broad discretion over allocation of net proceeds.